Immunovaccine in research pact with NRC
The collaboration aims to design a carbohydrate-based vaccine, using the DepoVax formulation, that can produce antibody levels specific to the carbohydrate target and capable of neutralizing meningococci. The
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.